- Home
- AGEN vs FCO Comparison
AGEN vs FCO Comparison
Compare AGEN & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- FCO
- Stock Information
- Founded
- AGEN 1994
- FCO 1991
- Country
- AGEN United States
- FCO United Kingdom
- Employees
- AGEN N/A
- FCO N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- FCO Investment Managers
- Sector
- AGEN Health Care
- FCO Finance
- Exchange
- AGEN Nasdaq
- FCO Nasdaq
- Market Cap
- AGEN 87.7M
- FCO 85.6M
- IPO Year
- AGEN 2000
- FCO N/A
- Fundamental
- Price
- AGEN $4.66
- FCO $6.45
- Analyst Decision
- AGEN Buy
- FCO
- Analyst Count
- AGEN 4
- FCO 0
- Target Price
- AGEN $13.00
- FCO N/A
- AVG Volume (30 Days)
- AGEN 1.7M
- FCO 100.1K
- Earning Date
- AGEN 08-07-2025
- FCO 01-01-0001
- Dividend Yield
- AGEN N/A
- FCO 14.96%
- EPS Growth
- AGEN N/A
- FCO N/A
- EPS
- AGEN N/A
- FCO 0.43
- Revenue
- AGEN $99,524,000.00
- FCO N/A
- Revenue This Year
- AGEN $12.69
- FCO N/A
- Revenue Next Year
- AGEN N/A
- FCO N/A
- P/E Ratio
- AGEN N/A
- FCO $12.30
- Revenue Growth
- AGEN N/A
- FCO N/A
- 52 Week Low
- AGEN $1.38
- FCO $4.73
- 52 Week High
- AGEN $18.74
- FCO $6.63
- Technical
- Relative Strength Index (RSI)
- AGEN 49.92
- FCO 64.78
- Support Level
- AGEN $4.71
- FCO $6.16
- Resistance Level
- AGEN $5.22
- FCO $6.41
- Average True Range (ATR)
- AGEN 0.36
- FCO 0.09
- MACD
- AGEN -0.12
- FCO 0.00
- Stochastic Oscillator
- AGEN 14.76
- FCO 100.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.